Overview
The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and/or pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:
- What is the association between antiXa and VTE?
- What is the association between antiXa and symptomatic, respectively incidental, VTE?
- How is pharmacological anticoagulation with enoxaparin related to measured antiXa?
- What is the association between antiXa and bleeding complications.
- What is the incidence of venous thromboembolism in patients treated at an intensive care unit?
- How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit/hospital.
Eligibility
Inclusion Criteria:
- Age over 18 years at the time of intensive care unit admission
- Admission to a participating intensive care unit within the last 24 hours
- Expected discharge is later than 48 hours after enrolment
Exclusion Criteria:
- Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE/kg when given twice daily or of at least 150 IE/kg when given once daily
- Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment
- Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period
- Estimated life expectancy below 48 hours or comfort terminal care order in place
- Previously diagnosed heparin-induced thrombocytopenia
- Pre-operative admission for elective surgery
- Previous enrolment in the study